IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+16.64%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$762M
AUM Growth
+$762M
(+58%)
Cap. Flow
+$253M
Cap. Flow
% of AUM
33.18%
Top 10 Holdings %
Top 10 Hldgs %
36.2%
Holding
102
New
30
Increased
25
Reduced
12
Closed
27
Top Buys
| 1 |
Cigna
CI
|
$50.5M |
| 2 |
Zimmer Biomet
ZBH
|
$43.7M |
| 3 |
McKesson
MCK
|
$30.8M |
| 4 |
Tenet Healthcare
THC
|
$18.9M |
| 5 |
Boston Scientific
BSX
|
$17M |
Top Sells
| 1 |
Stryker
SYK
|
$14.3M |
| 2 |
Teleflex
TFX
|
$11.7M |
| 3 |
Cardinal Health
CAH
|
$11.5M |
| 4 |
Biogen
BIIB
|
$11.1M |
| 5 |
uniQure
QURE
|
$10.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$80.3B
| $50.5M | 6.25% | +180,000 | New | +$50.5M |
|
|
2
Zimmer Biomet
ZBH
$21B
| $43.7M | 5.41% | +300,000 | New | +$43.7M |
|
3
Inspire Medical Systems
INSP
$2.77B
| $33.4M | 4.14% | 103,000 +23,000 | +29% | +$7.47M |
|
|
4
McKesson
MCK
$85.4B
| $30.8M | 3.81% | +72,000 | New | +$30.8M |
|
|
5
Boston Scientific
BSX
$156B
| $25.2M | 3.12% | 466,000 +314,000 | +207% | +$17M |
|
6
Cytokinetics
CYTK
$4.23B
| $21.2M | 2.63% | 650,000 +50,000 | +8% | +$1.63M |
|
7
Cooper Companies
COO
$13.4B
| $19.9M | 2.47% | 52,000 +12,000 | +30% | +$4.6M |
|
|
8
Tenet Healthcare
THC
$16.3B
| $18.9M | 2.34% | +232,000 | New | +$18.9M |
|
9
Revvity
RVTY
$10.5B
| $16.6M | 2.06% | 140,000 +55,000 | +65% | +$6.53M |
|
10
argenx
ARGX
$43.6B
| $15.6M | 1.93% | 40,000 +28,000 | +233% | +$10.9M |
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $15.3M | 1.89% | +300,000 | New | +$15.3M |
|
12
Encompass Health
EHC
$12.3B
| $14.9M | 1.84% | +220,000 | New | +$14.9M |
|
13
Guardant Health
GH
$8.41B
| $14.7M | 1.83% | 412,000 +62,000 | +18% | +$2.22M |
|
14
Hologic
HOLX
$14.9B
| $14.2M | 1.75% | 175,000 +100,000 | +133% | +$8.1M |
|
15
Eli Lilly
LLY
$657B
| $14.1M | 1.74% | +30,000 | New | +$14.1M |
|
16
Centene
CNC
$14.3B
| $13.5M | 1.67% | +200,000 | New | +$13.5M |
|
17
AbbVie
ABBV
$372B
| $13.5M | 1.67% | 100,000 +19,000 | +23% | +$2.56M |
|
18
Elevance Health
ELV
$71.8B
| $13.3M | 1.65% | 30,000 -21,000 | -41% | -$9.33M |
|
19
Schrodinger
SDGR
$1.44B
| $13.2M | 1.64% | +265,000 | New | +$13.2M |
|
20
Zentalis Pharmaceuticals
ZNTL
$122M
| $12.7M | 1.57% | 450,000 -150,000 | -25% | -$4.23M |
|
21
GSK
GSK
$79.9B
| $12.5M | 1.54% | +350,000 | New | +$12.5M |
|
22
Intuitive Surgical
ISRG
$170B
| $12.3M | 1.52% | +36,000 | New | +$12.3M |
|
|
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.2M | 1.52% | 120,000 +49,000 | +69% | +$5M |
|
24
HCA Healthcare
HCA
$94.5B
| $12.1M | 1.5% | 40,000 -5,000 | -11% | -$1.52M |
|
25
Danaher
DHR
$147B
| $12M | 1.49% | +50,000 | New | +$12M |
|